Comparison of Ranolazine and Trimetazidine on Glycemic Status in Diabetic Patients with Coronary Artery Disease – A Randomized Controlled Trial

Selvarajan, Sandhiya; Dkhar, Steven Aibor; Pillai, Ajith Ananthakrishna; George, Melvin; Jayaraman, Balachander; Chandrasekaran, Adithan

doi:10.7860/jcdr/2015/10594.5448

Cited by 12 publications

(14 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The type of antidiabetic drugs used for group 1 and group 2 patients with a history of diabetes was similar. The majority of patients were taking either metformin and/or sulfonylurea which is similar to the study conducted by Selvarajan S et al 12 There were no major changes in the antidiabetic drugs in both the groups between 0 and 3 months. Hence, the effect of ranolazine on FBS and HbA1c does not appear to be attributable to use of concurrent anti diabetic therapy in ranolazine-treated patients group 2 ( Table 1).…”

Section: When Intergroup Comparison Is Done For Mean Reduction Insupporting

confidence: 81%

“…The baseline characteristics and concomitant medications were similar in both the groups, hence comparable which is similar to the study conducted by Selvarajan S et al where ranolazine is compared with trimetazidine to evaluate for the reduction in HbA1c levels. 12 Patients in group 2 had increased frequency of angina per week compared to group 1. Ranolazine is indicated in patients with chronic angina who are inadequately controlled with first line antianginal drugs as an add on therapy therefore patients in group 2 received ranolazine as an add on drug ( Table 1).…”

Section: When Intergroup Comparison Is Done For Mean Reduction Inmentioning

confidence: 86%

“…Ranolazine is a novel oral anti anginal drug known to reduce HbA1c and fasting blood glucose levels in angina patients with diabetes. 12 The present open labelled prospective study was conducted to assess the effect of ranolazine on HbA1c and fasting blood sugar levels in patients of diabetes mellitus with chronic angina.…”

Section: When Intergroup Comparison Is Done For Mean Reduction Inmentioning

confidence: 99%

“…A study done by Selvarajan S, showed that ranolazine when given at 500mg b.d for 12 weeks had no effect on HbA1c and FBS levels. 12 Hence it was decided to use 1000mg b.d in our study.…”

Section: When Intergroup Comparison Is Done For Mean Reduction Inmentioning

confidence: 99%

See 3 more Smart Citations

Effect of ranolazine on HbA1c and blood glucose levels in diabetic patients with chronic angina

Shilpa¹,

Shashikala²,

Siddesh³

et al. 2019

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

Background: Diabetes mellitus is the fifth leading cause of death worldwide and is one of the common co-morbid conditions associated with coronary artery disease (CAD). The overall prevalence of CAD is 7.4% but the prevalence of CAD in diabetics is 9%. Hence treatment of hyperglycemia is a key goal of secondary preventive therapy with a target of reducing HbA1c to <7%. The risk of CAD has been reported to occur 2 to3 decades prior in diabetics compared to non-diabetics. Hence discovery of drugs with potential role in both diabetes and CAD seems to be necessary. Ranolazine is a novel oral anti anginal drug known to reduce HbA1c and fasting blood glucose levels in angina patients with diabetes. The objective of this study is to show the effect of ranolazine (antianginal drug) on HbA1c and fasting blood glucose levels in diabetic patients with chronic angina.Methods: Patients were divided into: Group 1 continued with previous antidiabetic drugs and antianginal drugs. Group 2 were prescribed Tab ranolazine 1000mg b.d (orally) as add on therapy along with previous antidiabetic drugs and antianginal drugs.Results: There was a significant reduction in HbA1c and FBS levels in Group 2 patients who were on ranolazine. Reduction of HbA1c in group1 and Group 2 was 0.21±0.65% and 1.30±1.16% respectively. Reduction of FBS in group1 and group2 was 10.66±27.80mg/dl and 29.97±31.49mg/dl respectively.Conclusions: From the present study we can conclude that ranolazine, an antianginal drug when given at a dose of 1000mg bd in diabetic patients with chronic angina reduces HbA1c and FBS levels.

show abstract

Section: When Intergroup Comparison Is Done For Mean Reduction Insupporting

confidence: 81%

Section: When Intergroup Comparison Is Done For Mean Reduction Inmentioning

confidence: 86%

Section: When Intergroup Comparison Is Done For Mean Reduction Inmentioning

confidence: 99%

“…A study done by Selvarajan S, showed that ranolazine when given at 500mg b.d for 12 weeks had no effect on HbA1c and FBS levels. 12 Hence it was decided to use 1000mg b.d in our study.…”

Section: When Intergroup Comparison Is Done For Mean Reduction Inmentioning

confidence: 99%

See 2 more Smart Citations

Effect of ranolazine on HbA1c and blood glucose levels in diabetic patients with chronic angina

Shilpa¹,

Shashikala²,

Siddesh³

et al. 2019

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

show abstract

“…Patients with coronary heart diseases suffer from dyslipidemia and enhanced blood viscosity of varying degrees, and blood viscosity gradually increases under continuous disease progression [5]. Statins lipid-lowering drugs are usually used in clinical treatment because these drugs can effectively lower the TC and LDL-C levels of patients, provide antiinflammation, antioxidation, and improvement effects of vascular endothelial functions, and inhibit the formation of atherosclerotic plaques [6].…”

Section: Discussionmentioning

confidence: 99%

Clinical effect of atorvastatin-trimetazidine combined treatment of coronary heart disease

Song¹,

Wang²

2018

biomedicalresearch

View full text Add to dashboard Cite

show abstract

Ranolazine for stable angina pectoris

Salazar

Flores

Veramendi-Espinoza

et al. 2017

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

We found very low quality evidence showing that people with stable angina who received ranolazine as monotherapy had increased risk of presenting non-serious adverse events compared to those given placebo. We found low quality evidence indicating that people with stable angina who received ranolazine showed uncertain effect on the risk of cardiovascular death (for ranolazine given as monotherapy), all-cause death and non-fatal AMI, and the frequency of angina episodes (for ranolazine given as monotherapy) compared to those given placebo. Moderate quality evidence indicated that people with stable angina who received ranolazine showed uncertain effect on quality of life compared with people who received placebo. Moderate quality evidence also indicated that people with stable angina who received ranolazine as add-on therapy had fewer angina episodes but increased risk of presenting non-serious adverse events compared to those given placebo.

show abstract

Comparison of Ranolazine and Trimetazidine on Glycemic Status in Diabetic Patients with Coronary Artery Disease – A Randomized Controlled Trial

Cited by 12 publications

References 30 publications

Effect of ranolazine on HbA1c and blood glucose levels in diabetic patients with chronic angina

Effect of ranolazine on HbA1c and blood glucose levels in diabetic patients with chronic angina

Clinical effect of atorvastatin-trimetazidine combined treatment of coronary heart disease

Ranolazine for stable angina pectoris

Contact Info

Product

Resources

About